MedDataX Logo

Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

NCT ID: NCT02262637

Last Updated: 2014-10-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4814 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

NCT02242370

Hypertension
COMPLETED PHASE4

Study to Evaluate Efficacy and Tolerability of Micardis®/Micardis® Plus in Patients With Hypertension

NCT02242357

Hypertension
COMPLETED

Evaluation of the Effect of Telmisartan (Micardis® 80 mg/ MicardisPlus® 80/12.5 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients

NCT00904371

Hypertension Cardiovascular Diseases
COMPLETED

Evaluation of Efficacy and Tolerability of Micardis® / MicardisPlus® Under Usual Daily-practice Prescribing in Patients With Hypertension

NCT02242383

Hypertension
COMPLETED

Micardis® in Patients With Essential Hypertension

NCT02187705

Hypertension
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypertensive patients - Cardiologists

Micardis®

Intervention Type DRUG

MicardisPlus®

Intervention Type DRUG

Hypertensive patients - Nephrologists

Micardis®

Intervention Type DRUG

MicardisPlus®

Intervention Type DRUG

Hypertensive patients - Diabetologists

Micardis®

Intervention Type DRUG

MicardisPlus®

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Micardis®

Intervention Type DRUG

MicardisPlus®

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \>= 18 years

Exclusion Criteria

* Age \< 18 years
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Boehringer Ingelheim

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

502.442, 502.443

Identifier Type: OTHER

Identifier Source: secondary_id

502.441

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients
NCT00879411 COMPLETED
Post-Marketing Surveillance Study of Micardis® Plus in Patients With Hypertension
NCT02238275 COMPLETED
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
NCT00257491 COMPLETED PHASE3
Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients
NCT01108809 COMPLETED
Relative Bioavailability of Telmisartan and HCTZ in Two Experimental Formulations Compared to the Standard Formulation Telmisartan and HCTZ in Healthy Female and Male Subjects
NCT02262572 COMPLETED PHASE1
Study to Evaluate the Effect of the Treatment With Micardis® or MicardisPlus® on Blood Pressure
NCT02242864 COMPLETED
Additional Effect of A Life Style Program on Antihypertensive Treatment With Telmisartan
NCT01108796 COMPLETED
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With Hypertension
NCT02242838 COMPLETED
Post Marketing Surveillance Study in Rehabilitation Clinics (Cardio, Nephro, Diabetes, Pulmo)
NCT02262611 COMPLETED
Telmisartan Versus Amlodipine in Patients With Mild-to-Moderate Hypertension
NCT02177409 COMPLETED PHASE3
A Study of a Hypertensive Population Under Treatment With Micardis® and Micardis Plus® to Control the Early Morning BP Rise (SURGE II)
NCT02242396 COMPLETED
Efficacy and Safety of Chronic Administration of Telmisartan as Monotherapy or in Combination With Hydrochlorothiazide or Other Antihypertensive Medications in Patients With Mild to Moderate Hypertension
NCT02177422 COMPLETED PHASE3
Study of Hypertensive Population Under Treatment With Telmisartan in Real Clinical Conditions With the Goal to Control Early Morning Blood Pressure Rise
NCT00946829 COMPLETED
Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients
NCT00863980 TERMINATED NA
Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM
NCT00274612 COMPLETED PHASE4
Study to Evaluate the Effect of Micardis® / MicardisPlus® on Metabolic Parameters in Patients With Essential Hypertension and Diabetes Mellitus
NCT02242825 COMPLETED
Telmisartan+HCTZ (Hydrochlorothiazide), Hypertension
NCT00659607 COMPLETED
Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension
NCT00281580 COMPLETED PHASE3
PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)
NCT00274638 COMPLETED PHASE4
Post-marketing Surveillance Study With MicardisPlus® in Treatment of Morning Hypertension (Self-monitored by Patient)
NCT02243566 COMPLETED
Telmisartan-Induced Reduction in Intra-Myocellular Lipids Trial
NCT00147264 COMPLETED PHASE3
An Observational Cohort Study to Evaluate the Safety and Efficacy of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertensive Patients Under Real Life Conditions in Usual Clinical Practice
NCT00982735 COMPLETED
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® / LORZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
NCT02200653 COMPLETED PHASE4
Telmisartan With or Without Hydrochlorothiazide (HCTZ) Compared With Losartan With or Without HCTZ in Mild to Moderate Hypertensive Patients
NCT02172586 COMPLETED PHASE4
PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN
NCT00274599 COMPLETED PHASE4